Abstract
Allogeneic hematopoietic stem cell transplantation (allo-HCT) is a potentially curative therapy for patients suffering from hematological malignancies via the donor immune system driven graft-versus-leukemia effect. However, the therapy is mainly limited by severe acute and chronic graft-versus-host disease (GvHD), both being life-threatening complications after allo-HCT. GvHD develops when donor T cells do not only recognize remaining tumor cells as foreign, but also the recipient’s tissue, leading to a severe inflammatory disease. Typical GvHD target organs include the skin, liver and intestinal tract. Currently all approved strategies for GvHD treatment are immunosuppressive therapies, with the first-line therapy being glucocorticoids. However, therapeutic options for glucocorticoid-refractory patients are still limited. Novel therapeutic approaches, which reduce GvHD severity while preserving GvL activity, are urgently needed. Targeting kinase activity with small molecule inhibitors has shown promising results in preclinical animal models and clinical trials. Well-studied kinase targets in GvHD include Rho-associated coiled-coil-containing kinase 2 (ROCK2), spleen tyrosine kinase (SYK), Bruton’s tyrosine kinase (BTK) and interleukin-2-inducible T-cell kinase (ITK) to control B- and T-cell activation in acute and chronic GvHD. Janus Kinase 1 (JAK1) and 2 (JAK2) are among the most intensively studied kinases in GvHD due to their importance in cytokine production and inflammatory cell activation and migration. Here, we discuss the role of kinase inhibition as novel treatment strategies for acute and chronic GvHD after allo-HCT.
Highlights
Patients suffering from hematological malignancies have only access to a very limited number of therapeutic interventions
Since graft-versus-host disease (GvHD) involves a vast number of pathways and signaling cascades for immune cell activation, proliferation and effector cytokine production, as well as in inflammatory signaling and fibrosis, the disease is hard to treat with only a single compound
Preclinical and clinical analyses revealed that treatment with single compounds has therapeutic limitations, as GvHD is mediated by a variety of pathways and by a single activated molecule
Summary
Patients suffering from hematological malignancies have only access to a very limited number of therapeutic interventions. *All clinical trials are registered at https://clinicaltrials.gov; AEs, adverse events; aGvHD, acute GvHD; BAT, best available therapy; BTK, Bruton’s tyrosine kinase; cGvHD, chronic GvHD; CR, complete response; DLT, dose-limiting toxicities; FFS, failure-free survival; GvHD, Graft-versus-Host Disease; HCT, hematopoietic stem cell transplantation; JAK, Janus kinase; MR, malignancy relapse/progression; MTD, maximum tolerated dose; mTOR, mammalian target of rapamycin; NRM, non-relapse mortality; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PK, pharmacokinetics; PR, partial response; PROs, patient reported outcomes; ROCK2, rho-associated coiled-coil containing protein kinase 2; ROM, range of motion; RR, relapse rate; SR, steroid-refractory; SYK, Spleen tyrosine kinase; Tregs, regulatory T-cells; TRM, treatment-related mortality; TTF, treatment to failure time; URD, unrelated donor; VGPR, very good partial response.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
